15250-m-cuypers

96 Chapter 5 status, including scales assessing physical, role, cognitive and emotional functioning, fatigue and sleep problems, and overall health and quality of life. This core instrument is supplemented with the prostate cancer-specific HRQoL questionnaire EORTC QLQ- PR25 43 . This 25-item questionnaire assesses urinary, bowel and sexual symptoms and functioning, and the side-effects of hormonal treatment, though hormonal treatment is not offered as initial treatment in this study’s sample. Health outcomes are further assessed by means of an evaluation of side-effect impact 44,45 and health status acceptance and subjective control 46 . Other measures Table 2 shows an overview of the other measures. Decision aid users are asked to evaluate the DA by indicating for 25 statements if it applies to the responder or not. The first 11 statements are formulated negatively (for example ‘I found the decision aid too difficult’), followed by 14 positively formulated statements (for example ‘I found the decision aid pleasant to use’). Although literature reports positive effects from the usage of DAs in general 47 , there may be subgroups that will not benefit from DA-usage. To identify these subgroups, additional measures on (health) skills and personality are included. Objective measures for health literacy and health numeracy are used, with the HRS Experimental numeracy module 48 and the STOHFLA-brief 49 , respectively. The Decision Self-Efficacy Scale is used as a subjective measure of the perceived ability to make a decision 50 . Table 2. Other measures Measures Instrument T1 T2 T3 Implementation (intervention only) DA-Acceptability Self-developed X (health) skills Self-efficacy Decision self-efficacy scale X Health numeracy HRS Experimental numeracy module X Health literacy STOHFLA-brief X Psychosocial variables Anxiety and depression HADS, PC-max X X X Personality LOT-R, BFI-10 X Information seeking preferences API, NFC-short, Maximization scale X Sociodemographics and other healthcare utilization X X X